Find A Doctor

Specializes in gastrointestinal oncology, including primary liver cancer, pancreas, gallbladder, and bile duct tumors. Research focuses on improving the effectiveness of cancer therapy by incorporating small novel biological molecules that target cancer into the treatment of chemotherapy-resistant gastrointestinal malignancies, particularly hepatobiliary and pancreatic cancers.

Specialist in thoracic oncological intervention. Well versed in lung biopsy and thermal ablation of primary and metastatic pulmonary tumors. Practices radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation of thoracic tumors.

Pediatric interventional radiologist who uses state-of-the-art radiology imaging equipment to perform minimally invasive procedures, which only require tiny incisions.

Specialty interests include general surgery, liver transplantation, living donor liver transplantation (LDLT), pediatric liver transplantation and hepatocellular carcinoma.

Hepatobiliary and liver transplant surgeon; nationally renowned expert in living donor liver transplantation. In addition to transplantation, provides care for a full spectrum of liver issues, including liver tumors and liver cancer. Active researcher of liver transplant topics, such as downstaging complex hepatobiliary tumors to resectability.

Specializes in oncology, with an interest in translational research and a growing expertise in the care of gastrointestinal (GI) cancer patients, collaborating closely with laboratory-based researchers to move laboratory findings into patients and bring novel compounds to the clinic. Previously developed a research program in hepatobiliary cancer at Johns Hopkins with her particular focus on studying the impact of epigenetic therapies as immune sensitizers. Actively involved with two current clinical trials designed specifically for FLC – one studying a therapeutic peptide vaccine in combination with checkpoint inhibition, and another studying the impact of glutamine antagonism on the cancer.

Surgical oncologist, with focus on abdominal and liver cancers. Active researcher into treatment of advanced carcinomas in the peritoneal cavity; Developed Hyperthermic Intraperitoneal Chemoperfusion (HIPEX), which delivers chemotherapy to patients with disease confined to peritoneal cavity.

Specializes in pediatric surgical oncology, neonatal surgery, burn and trauma care.

Research primarily focused in the areas of gastrointestinal cancer clinical trials, cancer clinical trials, biologic therapies, phase I cancer clinical trials and cancer guideline development.

Areas of expertise includes pancreas and liver cancer

Transplant surgery

Liver and transplant surgery; Founding Chief of the Division of Liver and Pancreas Transplantation and Director of the Pfleger Liver Institute, which includes the Dumont-UCLA Transplant Center and the Dumont-UCLA Liver Cancer Center.

Gastrointestinal Surgical Oncology; Hepatobiliary and Pancreatic Surgery

Co-directs the Institute for Translational Oncology Research (ITOR). Special interest in GI malignancies, especially colorectal and upper GI cancers, neuroendocrine carcinomas and hepatobiliary carcinomas.

Surgeon specializing in cancer of the liver, liver, biliary and pancreatic surgery. Former director of the Liver Transplant and Pancreaticobiliary Surgery Program at Cedars-Sinai in Los Angeles for 20 years.

Clinical interests include understanding molecular mechanisms of liver cancer and biology of high risk disease and targeted therapy for treatment of aggressive pediatric liver cancer.

Surgical Oncologist who specializes in treating diseases of the liver, bile duct, gallbladder, pancreas and abdominal sarcomas (GIST); His clinical research has focused on liver, bile duct, gallbladder, and pancreas cancers.

Medical Director for the Institute for Translational Oncology Research, which includes conduct and oversight of phase I and first-in-human clinical trials for new cancer medications as well as management of the Biorepository Services at GHS Cancer Institute.

Clinical expertise includes liver surgery, pancreas surgery, abdominal wall reconstruction, HIPEC, radiofrequency and microwave ablation.

Clinical interests include liver cancer resection and liver transplantation.

Specializes in the care of patients with hepato-pancreatico-biliary (HPB) pathologies, some of the most difficult cases to treat in general surgery/surgical oncology. Academic practice is devoted to clinical care, teaching, research, and administration.

Splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. Research interests are focused in the development of targeted therapeutics for solid tumors across histologies and the development of these targeted agents in Hepato-biliary and breast cancers.

Internationally recognized expert in cancer of the liver, pancreas, gallbladder and bile ducts.

Specializes in solid tumor treatment. Research interests include phase I clinical trials and therapy of childhood liver tumors.

Specializes in oncology. Member of St. Jude's Solid Tumor Division, which develops and tests novel therapeutic interventions for the treatment of pediatric solid tumors, specifically for those at high risk of treatment failure. Research interests include developing early phase clinical trials that lead to the identification of therapeutic biomarkers and novel combination therapies for high risk sarcomas and liver tumors.

Solid organ transplantation, pediatric transplantation, living-related organ donation, stem cell and regenerative medicine, immunology, liver cancer, liver surgery, hepatobiliary, laparoscopic liver surgery; Gallbladder; liver transplantation; kidney transplantation

Clinical and research focus is on pancreatic, liver, and biliary tract malignancies including multi-disciplinary care, clinical trials, and basic science research.

Gastrointestinal cancer specialist, caring for patients with hepatobiliary cancers, including fibrolamellar. Researches new therapies for hepatobiliary cancers and predictive biomarkers to better apply existing therapies.

Specialist in gastrointestinal surgical oncology with a particular focus in hepatopancreaticobiliary (liver, pancreas, and bile duct) surgery and gastric (stomach) tumors. Board certified and trained in the latest surgical techniques for upper gastrointestinal malignancies, including both advanced laparoscopic and robotic techniques.

Specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. Research focused on finding new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors.

Specializes in caring for people with gastrointestinal cancers, including malignancies of the liver, bile ducts, gallbladder, pancreas, colon, rectum, anus, stomach and esophagus. His research focuses on new targeted therapies, immunotherapies, novel drug combinations and other experimental therapies for patients with liver and biliary-tract cancers. Other areas of expertise include analyzing treatment outcomes data for patients with gastrointestinal cancers, as well as the identification of new treatments for fibrolamellar hepatocellular carcinoma.

Research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells. As the Director of the Liver Tumor Center, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently optimizing this strategy for a smooth transition into the clinic.

Biliary surgery, hepatobiliary cancer, liver cancer, liver surgery, liver transplantation, living donor liver transplantation

Extensive training in hepatobiliary, pancreatic, and colorectal surgery.

Pediatric surgeon at Hasbro Children’s Hospital and an assistant professor of surgery and pediatrics at The Warren Alpert Medical School of Brown University. He specializes in pediatric oncology and genomic research.

More than 20 years of experience in diagnosing and treating men and women with benign and malignant (cancerous) diseases of the liver, bile ducts, gallbladder, and pancreas. Most of his patients have primary liver cancer, pancreatic cancer, bile duct cancer, or colon cancer that has spread (metastasized) to the liver.

Clinical interests include benign and malignant tumors of the liver, hepatocellular carcinoma and
living donor and deceased donor liver transplantation

Research interests focused on liver cancer; Founder and Director, Hepatocellular Carcinoma Interdisciplinary Research Group (HIRG), Houston, TX.

Specializes in hepatobiliary surgery, liver transplantation, abdominal organ transplantation

Noted pioneer in multiple-organ transplantation, pediatric and adult liver transplantation. Dr. Kato is Surgical Director of Adult and Pediatric Liver and Intestinal Transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and is a professor of surgery at Columbia University College of Physicians and Surgeons.

Pediatric and young adult oncologist, with expertise in fibrolamellar. Board-certified in pediatric hematology-oncology. Retired Associate Professor of Hematology/Oncology at Rush University.

For more information, contact paulkentmd@fibrofighters.org.

Specializing in hepatology, Dr. Kim sees patients with chronic viral hepatitis, autoimmune liver diseases, fatty liver disease, abnormal liver enzymes, cirrhosis, portal hypertension, hepatocellular carcinoma and liver transplantation. She has research interests in liver lesions and hepatocellular carcinoma, and is board certified in internal medicine and gastroenterology. Past recipient of joint Cancer Research Institute and Fibrolamellar Cancer Foundation Research Fellowship.

Director of the Pediatric Transplant Center at BCH. Under his leadership, the Pediatric Transplant Center has grown into one of the busiest and most comprehensive pediatric transplant centers in the country.

Specializes in benign and malignant disease of the liver, bile ducts, and gallbladder; pancreatic cancer; pancreas cysts; adrenal tumors; gastrointestinal neuroendocrine tumors; general surgical oncology.

Specialist in colorectal, liver, pancreatic and stomach cancers

Specializes in oncology. with a focus on the diagnosis, management and treatment of patients with hepatobiliary and pancreatic cancer. He also has a role in the developmental therapeutics team at the UW Carbone Cancer Center. Runs an independent research laboratory in the UW Center for Human Genomics and Precision Medicine, where his research interests included improving the modeling of patient-derived cancer organoids.

Recognized as a world-renowned leader in precision oncology and rare cancer research, having authored over 950 scientific and medical publications. Chairs the Early Therapeutics and Rare Cancers Committee (SWOG NCI) — one of the largest clinical trials cooperative groups in the country. Principal investigator for more than 100 early-phase clinical trials, leading eight life-changing drugs to FDA approval. Currently running an innovative precision medicine trial (I-PREDICT) at the Medical College of Wisconsin that is open to fibrolamellar and other rare disease patients.

Pediatric surgery for the treatment of children and adolescents with cancer, including children with liver tumors. Chairperson of the Surgical Committee of the Children’s Oncology Group. Member and past chairman of the Pediatric Surgical Association Cancer Committee.

One of the main authors of the MD Anderson Manual of Medical Oncology on hepatocellular carcinoma (liver cancer) and biliary tract cancers (bile duct and gallbladder cancer) and a Principal Investigator (PI) and co-PI of clinical trials and research studies in the areas of liver, bile duct, and pancreas cancer, New PI for FCF-sponsored clinical trial at MD Anderson, working closely with Dr. A. Kaseb.

Clinical interests include liver transplant oncology, simultaneous liver kidney transplantation, and liver transplant futility. Dr. Lunsford has received funding from the Association of Women Surgeons and the National Institutes of Health (NIH) NIDDK for her translational research in the mechanism and impact of pre-transplant immune dysfunction in liver transplant recipient outcomes. She serves on several national and international committees and is well-published in the field of transplant surgery and immunology.

Clinical interests center around gastrointestinal cancers, including liver cancer.

Specializes in the treatment of cancers of the liver, pancreas, melanoma and sarcoma.

International expert in hepatoblastoma and liver tumors, clinically specializes in pediatric surgical oncology. Driving force behind establishing the Pediatric Liver Transplant program at Primary Children’s in 1997 and served as the Pediatric Surgical Director of the Liver Transplant Program from 1997 to 2009. Served as chair of the national Children’s Oncology Group (COG) Liver Committee since 2008 and has led multiple national and international research investigations in the study of liver tumors in children.

Experienced hepatobiliary surgeon with an extensive background in the evaluation and treatment of people with liver, bile duct, and pancreatic tumors. Leads successful cancer research laboratory, where he investigates immunologic regulation of liver and pancreatic cancer.

Leads the Dana-Farber/Boston Children’s pediatric Liver Tumor Program. Strong interest in translational research and a growing expertise in the care of pediatric solid tumor patients. Works closely with surgeons, interventional radiologists, and preclinical researchers to bring innovative care to patients with all types of primary liver tumors. Current Chair of the Liver Tumor Committee of the Children's Oncology Group, the most experienced organization in the world in clinical development of new therapeutics for children and adolescents with cancer.

Specializes in treating rare pediatric tumors; kidney cancers, liver cancers, sarcomas; relapsed and refractory solid tumors in children and young adults.

Specializes in the treatment of gastrointestinal tumors, esophageal cancer, gallbladder cancer, gastrointestinal cancers, liver cancer, pancreatic cancer, stomach cancer, with precision medicine and targeted therapies.

Co-director of the Gastrointestinal Research Program for The US Oncology Network, as well as the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center.

Surgical oncologist with a focus on treating patients with liver, gallbladder, pancreatic and neuroendocrine tumors. Serves as the surgeon-in-chief of The Ohio State University Wexner Medical Center, the chair of the Department of Surgery in the College of Medicine and professor of surgery.

Research interests include better understanding the factors associated with prognosis and staging around gastrointestinal cancers, as well as studying patient-physician communication, patient engagement, and patient perception around the goals of cancer care.

Practice includes pancreatic and liver surgery operations.

Specializes in treating patients with gastrointestinal malignancies and sarcoma with a clinical focus on hepatic, biliary and pancreatic malignancy.

Focused on treating patients with extensive liver tumors — both primary, as well as secondary.

Specializes in liver, kidney and pancreas transplant. His expertise includes treating liver cancer, bile duct cancer, liver cysts, and benign tumors of the liver. His research interests include factors influencing patient and graft survival following liver transplant; socioeconomic factors and impact on liver cancer diagnosis; and treatment and access to transplant.

Surgical oncologist with a focus on pancreatic cancer, liver cancer, biliary cancer, gastric cancer and multivisceral resections. Special interests include quality of cancer care and multidisciplinary cancer care.

Expertise includes liver surgery, hepatic lobectomy, hyperthermic intraperitoneal chemotherapy (HIPEC) and radiofrequency ablation.

Clinical expertise in the areas of liver surgery, pancreas surgery, melanoma, thyroid cancer, colorectal surgery, HIPEC, and abdominal wall reconstruction.

Research focused on clinical trials of novel chemotherapy agents in cancers of the liver, gallbladder, biliary tract, pancreas, and colon. Involved in many Phase I trials of new drugs in all solid tumors. Currently, focusing on bringing clinical trials to underserved regions of NC and on cancer disparities research. Serves as a member of the National Cancer Institute Central Institutional Review Board (NCI CIRB), early phase emphasis.

One of 5 doctors at Providence Sacred Heart Medical Center and Children's Hospital who specialize in Pediatric Hematology-Oncology

Specializes in treatment of Gastrointestinal Cancers and Phase I Clinical Trials.

Specializes in pediatric surgical oncology. Dr. Vasudevan is the surgical lead of the Texas Children’s Liver Tumor Program and is actively involved in the liver cancer committee of the Children’s Oncology Group. Actively involved with taking care of patients with hepatoblastoma, hepatocellular carcinoma, embryonal sarcoma of the liver, benign tumors of the liver (mesenchymal hamartoma, hemangiomas, FNH, cysts), neuroblastoma, and renal tumors.

Past President of the Americas Hepato-Pancreato-Biliary Association. Dr. Vauthey’s clinical research focuses on methods to measure and to improve outcome after hepatic resection for hepatobiliary malignancies.

Associate Professor of Surgery at The Johns Hopkins University School of Medicine and an attending surgeon at The Johns Hopkins Hospital. His primary clinical interests are cancers and benign disease of the liver, pancreas, bile duct and gallbladder.

Specialist in oncology, caring for patients with gastrointestinal cancers. Clinical activities focused on cancers of the liver, including hepatocellular carcinoma, biliary tract cancers, and fibrolamellar hepatocellular carcinoma. Co-leads the Liver Cancer Multidisciplinary Clinic. Directs laboratory research focused on the discovery of novel cancer immunotherapies for hepatobiliary cancers. Principal investigator for two current clinical trials designed specifically for FLC – one studying a therapeutic peptide vaccine in combination with checkpoint inhibition, and another studying the impact of glutamine antagonism on the cancer.

Board certified surgeon and founder of the UW Medicine Liver Tumor Clinic, the first clinic of its kind in the Pacific Northwest, and founder of the UW Medicine Liver Tumor Clinic. Dr. Yeung’s clinical expertise is in the surgical treatment of tumors of the liver including the primary liver and bile duct cancers hepatocellular carcinoma (HCC), fibrolamellar carcinoma (FLCC) and cholangiocarcinoma, as well as cancer that has spread to the liver.